Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoRapid

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by CHMP for adolescents

Semaglutide works by mimicking an intestinal hormone that is released after eating

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

The decision comes just weeks after Eli Lilly announced a similar series of price cuts

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by NICE

The drug, semaglutide, will be offered to eligible adults for a maximum of two years

- PMLiVE

Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs

Insulin manufacturers have come under fire recently over the cost of their insulin products

- PMLiVE

Medscape Education Wins Best Practice Award for Learner Outcomes at NAMEC

This year's winners have been announced  for the National Association of Medical Education Companies (NAMEC) awards. These awards recognize best practices-ideas or processes that can be implemented by NAMEC members to...

Medscape Education Global

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

- PMLiVE

California sues largest US insulin manufacturers and PBMs for overpricing

Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply

- PMLiVE

Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa

The African-made insulin products are expected to reach one million people per year by 2030

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links